AgNovos Bioscience
New York
About AgNovos Bioscience
AgNovos Bioscience is focused on improving the lives of millions of women globally. The Company has a regenerative technology that restores the structure and biomechanics of bone to transform the paradigm of treatment for patients with osteoporosis, a disease that impacts over 600MM people and causes over 12MM fractures annually. AgNovos seeks to prevent osteoporotic hip fractures which cause significant morbidity and mortality (25% die within 1 year). Current treatments leave a significant unmet need and the product is the first targeted approach to reduce fractures. The opportunity is significant with a target addressable market in excess of $50Bn.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $31.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2023)
- Website: agnovos.com
- Phone: (646) 502-5864
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/agnovos-bioscience-61484 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.